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Abstract
Purpose To ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients 
are struggling with therapeutic and financial implications.
Methods An online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinico-
pathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about 
COVID-19 as well as the validated 11-item COST measure.
Results Five-hundred-and-thirty-nine patients (39%:58% male:female) from 14 countries responded. 23% of the patients 
did not feel in control of their financial situation but 8% reported being very satisfied with their finances. The median COST 
score was 21.5 (range 1–44). Metastatic patients who have not started systemic therapy had a COST score (19.8 range 2–41) 
versus patients on oral systemic therapy had a COST score (23.9 range 4–44). Patients in follow-up after surgery had a median 
COST score at 20.8 (range 1–40). A low COST scores correlated (p < 0.001) were female gender (r = 0.108), younger age 
(r = 0.210), urban living situation (r = 0.68), a lower educational level (r = 0.155), lower income (r = 0.165), higher anxi-
ety about acquiring COVID-19 (r = 0.198), having metastatic disease (r = 0.073) and a higher distress score about cancer 
progression (r = 0.224).
Conclusion Our data highlight severe financial impact of COVID-19. Acknowledging financial hardship and thorough 
counseling of cancer patients should be part of the conversation during the pandemic. Treatment and surveillance of RCC 
patients might have to be adjusted to contemplate financial and medical needs.
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Introduction
Much has been written about how the COVID-19 crisis is 
placing immense strain on healthcare systems worldwide. 
As a consequence, there has been a rush to develop guide-
lines around every element of cancer care, ranging from use 
of surgery, radiation, systemic therapy to supportive care 
modalities [1–4]. Practice changes have been implemented 
to reduce touchpoints for patients and to preserve hospital 
resources for COVID-19 patients. However, less research 
has focused on how the crisis is impacting individuals being 
treated for cancer, including adverse effects of financial 
toxicity.
Advances in care for patients with renal cell carcinoma 
have dramatically changed over the last decade, improv-
ing outcomes and increasing overall survival for patients. 
However, these advances have occurred during a time when 
insurance plans have also increased cost-sharing, shifting a 
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greater proportion of treatment costs directly to the patient 
[5].
An estimated 2.7 billion people have been impacted by 
coronavirus lockdowns and according to the United Nations 
Conference on Trade and Development, the global economy 
could lose $2 trillion as a result of the crisis [6].
Advances in cancer care become meaningless if patients 
cannot afford them or if the patients’ prognoses continue to 
be determined by where they live or how good their insur-
ance is [7].
We conducted an online survey to ascertain (a) patient 




The survey was developed by the Kidney Cancer Research 
Alliance (KCCure), with multidisciplinary representation 
from two surgeons (MS, DP), medical oncologist (SKP), 
psychologist (CB) and patient advocate (DB). The survey 
included a total of 45 items (detailed subsequently) and was 
initially evaluated by a separate group of patient advocates 
for ease of interpretability. The open survey was then broad-
cast to the KCCure membership through a patient mailing 
list of n = 1532 subscribers maintained by the organiza-
tion and was also distributed through online social media 
platforms (specifically, Facebook and Twitter). Multiple 
responses from the same patient were prohibited by the 
system via anonymized IP address tracking. IRB was not 
obtained as the survey was a patient organization’s effort. No 
personal data were collected in the de-personalized question-
naire and prior to taking the survey patients gave informed 
consent for data use and analysis.
Survey composition
The survey is included as Supplementary Appendix  1. 
Briefly, the survey included demographic features includ-
ing age, gender, race, educational level and income level. 
Patients were queried regarding their perceived risk of 
COVID-19, and their anxiety level related to both COVID-
19 and cancer progression was quantified using a Likert 
scale ranging from 0 to 10.
Further questions were based on disease status. Patients 
in surveillance were queried regarding their current plan 
for surveillance. Patients receiving systemic treatment were 
queried regarding the nature of systemic therapy they were 
receiving.
The survey contained items pertaining to distress level, 
financial hardship, medical and behavioral expectations that 
were quantified on a Likert scale ranging from 0 to 3. To 
assess financial burden, the validated comprehensive score 
for financial toxicity (COST) patient-reported outcome 
measure was included. The lower the score, the worse the 
financial toxicity [8].
Statistical analysis
Descriptive statistics with graphical outputs were used to 
characterize survey results.
Pearson’s correlation (r) and Kendal’s tau test were used 
to analyze the COST questionnaire, financial burden and 
hardship, as well as medical and behavioral expectations. 
Significance levels were two-tailed. All statistical analyses 
were carried out with SPSS Statistics Vers. 26 (IBM Analyt-
ics, Armonk, NY, USA).
Results
Patient characteristics
Responses were received via e-mail and social media. With 
a response rate of 35% and 539 total respondents, 280 
patients (52%) had metastatic disease, 187 patients (35%) 
had prior surgery for localized disease and 23 patients (5%) 
had localized disease awaiting surgery (Table 1). Median 
age was 55 (range, 24–87) with 58% females and 39% males. 
Most patients had obtained a bachelor or graduate degree 
(44%) and live in the United States (87%). In addition, the 
majority of patients are receiving treatment at an academic 
center (37%), followed by regional centers (30%) and private 
practices (18%). Patients were predominantly white (88%) 
and well educated (58% had college or graduate degree. 
The majority had a household income that ranged between 
$50,000 and $99,999 (30%) or higher than $100,000 (38%). 
The majority of participants live in suburban areas (52%). 
Socioeconomic and clinical characteristics were statistically 
not significantly different between groups and are described 
in Table 1.
COVID‑19 and expected hardships
The majority of patients expect the pandemic to induce 
medical, behavioral, psychological and financial hardship. 
Only 17% do not expect medical, 25% behavioral, 16% psy-
chological and 13% financial hardship to occur as a result of 
COVID-19. Patients with an income of less than US $50,000 
were significantly more anxious about financial hardship 
than people with a high income (> US $100,000) (93% vs 
82%, p < 0.001).
Patients with a higher anxiety about acquiring COVID-19 
were significantly (p < 0.001) more likely to expect medical 
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(r = 0.212), behavioral (r = 0.178) and psychological hard-
ship (r = 0.304).
Financial anxiety
The majority of patients (59%) were concerned that their 
money in savings or retirements assets would not cover the 
cost of their treatment. Only 8% were satisfied with their 
financial situation and 25% were financially stressed. More 
than a quarter of the patients (26%) were concerned about 
losing their job and income and 32% claim that their cancer 
treatment has reduced their satisfaction with their present 
financial situation. Half of the patients do not feel in control 
of their financial situation and only 8% were confident about 
their finances.
Educational and income level
Patients with a higher educational level or a higher income 
were significantly more often living in urban areas and were 
more likely to be treated at an academic center (p < 0.001). 
Compared to patients with a lower educational or income 
level, they did not have higher anxiety related to acquiring 
COVID-19 and had the same level of cancer distress.
COST score assessment
The median COST score of all patients was 21.5 (range 
1–44). Detailed responses are shown in Table 2. Meta-
static patients who have not started systemic therapy had 
the lowest median COST score (19.8 range 2–41) versus 
patients on systemic therapy with oral treatments had the 
highest median COST score (23.9 range 4–44). Interestingly, 
patients in follow-up after surgery also had a lower median 
COST score at 20.8 (range 1–40) (see Fig. 1).
Factors significantly (p < 0.001) contributing to a lower 
COST score were female gender (r = 0.108), younger age 
(r = 0.210), urban living situation (r = 0.68), a lower edu-
cational level (r = 0.155), lower income (r = 0.165), higher 
anxiety about acquiring COVID-19 (r = 0.198), having meta-
static disease (r = 0.073) and a higher distress score about 
cancer progression (r = 0.224) (see Fig. 2).
Table 1  Patient characteristics Localized (no 
surgery), n = 23
Localized (prior 
surgery), n = 187
Metastatic, n = 280 Total, n = 539
Age 46 (24–67) 52 (26–86) 57 (31–87) 55 (24–87)
Gender
 Male 6 (26.1%) 49 (26.2%) 134 (47.8%) 310 (57.5%)
 Female 14 (60.8%) 134 (71.6%) 137 (48.9%) 211 (39.1%)
Race
 White 19 (82.6%) 165 (88.2%) 247 (88.2%) 473 (87.8%)
 Hispanic or Latino 0 (0.0%) 7 (3.7%) 11 (3.9%) 20 (3.7%)
 Black/African American 0 (0.0%) 4 (2.1%) 3 (1.1%) 7 (1.3%)
 Asian/Pacific Islander 0 (0.0%) 6 (3.2%) 7 (2.5%) 17 (3.2%)
 Native American 0 (0.0%) 2 (1.1%) 1 (0.3%) 3 (0.6%)
 Other 0 (0.0%) 3 (1.6%) 5 (1.8%) 10 (1.9%)
Type of practice
 Academic center 7 (30.4%) 57 (30.4%) 110 (39.3%) 199 (36.9%)
 Regional center 7 (30.4%) 47 (25.1%) 98 (35.0%) 162 (30.1%)
 Community hospital 3 (13.0%) 29 (15.5%) 30 (10.7%) 69 (12.8%)
 Private practice 3 (13.0%) 53 (28.3%) 38 (13.6%) 98 (18.2%)
Education level
 Less than high school 0 (0%) 3 (1.6%) 5 (1.8%) 9 (1.7%)
 High school 3 (13.0%) 26 (13.9%) 41 (14.6%) 81 (15.0%)
 Some college 6 (26.1%) 50 (26.7%) 65 (23.2%) 128 (23.7%)
 College/graduate degree 10 (43.5%) 107 (57.2%) 164 (58.6%) 310 (57.5%)
Income level
 $0–$24,999 3 (13.0%) 18 (9.6%) 20 (7.1%) 46 (8.5%)
 $25,000–$49,999 4 (17.4%) 35 (1.6%) 39 (13.9%) 85 (15.8%)
 $50,000–$99,999 6 (26.1%) 61 (32.6%) 85 (30.4%) 164 (30.4%)
 $100,000+ 7 (30.4%) 60 (32.1%) 117 (41.8%) 203 (37.7%)
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Table 2  COST responses – all patients
Not at all 
%
N
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Fig. 1  COST score and anxiety 
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Nationality and race were not correlated with financial 
distress in our dataset.
Discussion
Our study reveals that while patients experience height-
ened anxiety about increasing financial hardship related to 
Fig. 2  COST Score with selection “not at all” comparing different topics between metastatic and non-metastatic respondents
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COVID-19, they remain substantially concerned about can-
cer recurrence and progression. In the overall population, 
71% felt they had a heightened risk for COVID-19 infection; 
however, only 27% of patients contacted their treating physi-
cians to confirm this information. Patients with RCC seem 
unwilling to compromise planned surveillance for localized 
disease or planned systemic therapy for metastatic disease.
In our cohort, anxiety related to financial hardship is very 
high, mainly in patients with a moderate-to-high income and 
higher educational level.
The median COST score in our cohort of RCC patients 
is 21.5, which is somewhat lower than previously described 
cohorts of cancer patients in general, where it was at 23, 
indicating that pandemic might be increasing financial anxi-
ety [8–10].
Although oral systemic therapy based on tyrosine-kinase 
inhibitors has one of the highest co-pays for patients [9], this 
was the subgroup of respondents that expected the lowest 
financial hardship with a COST score of 23.9. Patients prior 
to surgery had the one of the lowest scores at 20.0, which 
could be a reflection of the fear of future costs versus actual 
cost. The lower rates of financial concern for patients receiv-
ing oral therapy could be due to the fact that these drugs 
are more commonly used in later-line treatment, reflecting 
a patient population that has more experience with treatment 
resulting in lower anxiety levels related to cost. In line with 
previous findings, younger patients were more likely to be 
anxious about financial hardship and might need additional 
counseling and a specific plan to address this anxiety [9].
Interestingly, patients who have been diagnosed with can-
cer, but have not yet had treatment, expressed higher anxiety 
about financial toxicity versus patients already on therapy. 
This was true for both metastatic patients and patients with 
localized disease. It could be that uncertainty related to 
future costs is a larger driver of financial toxicity rather than 
the actual realized cost of treatments for patients. This might 
indicate a need for increased counseling for patients who are 
newly diagnosed and could be experiencing anxiety due to 
the uncertainty related to potential financial costs (Fig. 2).
This concern related to uncertainty of future costs is 
also evident in the responses related to the COST question-
naire. When asked about confidence in covering the cost 
of treatment, 41% indicate that they are not at all confident 
that they have enough money in their savings or retirement. 
Yet, when asked whether their out-of-pocket expenses were 
more than they thought they would be, only 12% said “very 
much”. Only 6% of patients said that they feel satisfied with 
their current situation, but when asked if they were able to 
meet their monthly expenses, only 8% indicated that they 
were not able to do so. When asked if they felt in control of 
their financial situation, less than 10% indicated that they 
were. But again, when asked if their cancer or treatment had 
reduced their satisfaction with their present financial situa-
tion, only 16% said very much.
Uncertainty in cancer is one of the most significant forms 
of distress in cancer patients [11]. It could be that the specter 
of future costs, fear related to inability to care for their fam-
ily as their disease progresses, could be more important driv-
ers to consider when measuring financial toxicity.
Research related to patient-reported outcomes, while rap-
idly advancing in cancer care, is still poorly understood in 
renal cell carcinoma. Despite demands from patient advo-
cacy organizations, patient values concerning treatment 
decisions are yet to be defined and poorly described and 
understood [12]. Repeated assessment and analyses to differ-
entiate trends from principles are needed. Nonetheless, the 
high rates of anxiety highlight the need to address financial 
toxicity as a standard part of care for kidney cancer patients.
Comparing these numbers needs to be done with caution 
as there has not been a COST analysis in RCC so far. As the 
COST score observed in our patient cohort is comparable 
to other disease areas, we are confident it reflects on the real 
situation. As there is uncertainty and the fear of losing jobs 
and access to medical care is settling in, we believe it reflects 
the actual changes in the medical situation rather than being 
caused by a selection bias. Notably, reported cohorts so far 
had comparable demographics and baseline characteristics, 
with the majority of respondents being female, having a 
higher educational level and income [9, 10].
Limitations of our study include the use of data supplied 
by patients. Using this approach, confirmation of medical 
data (e.g., histology, stage, treatment regimen) is not feasi-
ble. Furthermore, the questionnaire outside the COST data 
was not validated. There is also likely some selection bias 
among survey respondents—our population was predomi-
nantly female, highly educated and primarily US-based, 
and a relatively high proportion was treated at academic 
centers. But compared to previous surveys, in our patient 
cohort with more than 1500 responses, no differences in 
characteristics were seen (data submitted for publication). 
Perhaps most importantly, the data for COVID-19 are evolv-
ing extremely rapidly. The distribution of cases is changing, 
as is the approach to infection prevention, prophylaxis and 
treatment [1, 3, 13–16]. As such, it is possible that the per-
spective of patients and physicians will change as the situa-
tion progresses. To supplement this, we plan to continue to 
survey the RCC community to obtain the patient perspective 
on management.
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Conclusion
Our data highlight severe financial impact of COVID-19 in 
patients with RCC. Acknowledging financial hardship and 
uncertainty related to future costs and providing thorough 
counseling of cancer patients should be part of the con-
versation during the pandemic. Younger patients, women 
and those with a lower income seem to be at highest need 
of financial advising. Treatment and surveillance of RCC 
patients might have to be adjusted to contemplate financial 
and medical needs.
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